MiniMed Study Links More Alert Responses To Better Diabetes Control

MiniMed (NASDAQ: MMED) presented new clinical evidence indicating that users of its Smart MDI system who responded to more alerts achieved an average of 8.1 percentage points more Time in Range (TIR) and 0.6 percentage points lower HbA1c over a six-month trial involving 143 participants with type 1 diabetes. The study highlights the importance of timely alerts in managing diabetes through multiple daily injections, which can significantly improve glucose outcomes. The Smart MDI system integrates a smart insulin pen with a continuous glucose monitor via the MiniMed Go app, streamlining diabetes management.